Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of IBR854 cell injection plus pemetrexed + cisplatin versus pemetrexed + cisplatin as first-line treatment for advanced non-squamous non-small cell lung cancer
CTR20262627Phase 2Active
- Sponsor
- InnoBairui
- Start
- Jul 2026
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IBR854 in Non-small cell lung cancer (NS-NSCLC), sponsored by InnoBairui. Started Jul 2026; status: active.
02
Drugs
IBR854
03
Conditions
Non-small cell lung cancer (NS-NSCLC)
Beyond the preview
Go deeper on CTR20262627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262627.